zolbetuximab-clzb
Jump to navigation
Jump to search
Indications
- incombination with with fluoropyrimidine- & platinum-containing chemotherapy, for first-line treatment locally advanced unresectable or metastatic HER2-negative CLDN18.2 positive, gastric or gastroesophageal junction adenocarcinoma
Dosage
- First dose: 800 mg/m2 intravenously
- Subsequent dosage:
- 600 mg/m2 intravenously every 3 weeks, or
- 400 mg/m2 intravenously every 2 weeks
Adverse effects
- vomiting, nausea, diarrhea, intestinal obstruction
- neutropenia, febrile neutropenia, pyrexia, sepsis
- pneumonia, respiratory failure, pulmonary embolism
Mechanism of action
More general terms
References
- ↑ FDA-approval Oct 18, 2023 FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma